VERV - Verve Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
VERV price evolution
VERV
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $5.9 | $3.15 | $2.09 | $1.4 |
| Inventory | ||||
| Total current assets | $637.95 | $498.26 | $473.07 | $517.79 |
| Long term investments | ||||
| Property, plant & equipment | $107.8 | $107.84 | $110.02 | $111.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $752.69 | $612.41 | $589.13 | $634.38 |
| Current liabilities | ||||
| Accounts payable | $6.64 | $1.05 | $3.15 | $3.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $37.01 | $34.58 | $33.03 | $33.55 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $153.19 | $152.04 | $123.91 | $124.9 |
| Shareholders' equity | ||||
| Retained earnings | -$544.3 | -$495.95 | -$450.19 | -$396.21 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $5.9 | $1.01 | ||
| Inventory | ||||
| Total current assets | $637.95 | $563.16 | $367.13 | $73.97 |
| Long term investments | ||||
| Property, plant & equipment | $107.8 | $110.66 | $9.06 | $3.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $752.69 | $679.22 | $384.12 | $78.41 |
| Current liabilities | ||||
| Accounts payable | $6.64 | $2.42 | $7.08 | $0.04 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $37.01 | $35.09 | $22.02 | $7.32 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $153.19 | $128.29 | $26.77 | $17.16 |
| Shareholders' equity | ||||
| Retained earnings | -$544.3 | -$344.24 | -$186.85 | -$66.54 |
| Other shareholder equity | $357.35 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.93 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $44.79 | $42.19 | $31.93 | $32.54 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.98 | $0.31 | $0.08 | $0.06 |
| Net income | ||||
| Net income | -$45.19 | -$40.95 | -$30.17 | -$31.34 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $87.07 | $40.63 | $13.64 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.14 | $0.16 | $0.28 | |
| Net income | ||||
| Net income | -$120.31 | -$45.7 | -$19.3 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $12.36 | $67.87 | $60.09 | -$239.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $289.36 | $0.95 | $0.51 | $377.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $212.28 | $8.56 | $27.09 | $60.11 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$239.1 | -$51.13 | -$12.76 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $377.09 | $92.63 | $17.95 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $60.11 | $6.23 | -$2.25 | |
News
Fundamentals
| Market cap | $545.92M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 81.97M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$147.64M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.70 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.80 |
|---|---|
| ROA | -22.81% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.24 |
| Quick ratio | N/A |